Enhanced Immunotherapy with LHRH-R Targeted Lytic Peptide in Ovarian Cancer.

ABSTRACT: Here, we examined the role of EP-100 [luteinizing hormone-releasing hormone (LHRH) ligand joined to a lytic peptide], improving the efficacy of immune checkpoint blockade. LHRH-R-positive murine ovarian cancer cells (ID8, IG10, IF5, and 2C12) were sensitive to EP-100 and were specifically killed at low micromolar levels through LHRH-R. EP-100 increased PD-L1 levels on murine ovarian cancer cells. In vivo syngeneic mouse models (ID8 and IG10) demonstrated that single-agent EP-100 reduced tumor volume, tumor weight, and ascites volume. The greatest reductions in tumor and ascites volume were observed with the combination of EP-100 with an anti-PD-L1 antibody. Immune profiling analysis showed that the population of CD8⁺ T cells, natural killer cells, dendritic cells, and mac

SUBMITTER: Kim MS 

PROVIDER: S-EPMC9399905 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature